| A novel pharmacologic inhibitor of the NLRP3 inflammasome limits myocardial injury after ischemia–reperfusion in the mouse C Marchetti, J Chojnacki, S Toldo, E Mezzaroma, N Tranchida, SW Rose, ... Journal of cardiovascular pharmacology 63 (4), 316-322, 2014 | 262 | 2014 |
| Inhibition of the NLRP3 inflammasome limits the inflammatory injury following myocardial ischemia–reperfusion in the mouse S Toldo, C Marchetti, AG Mauro, J Chojnacki, E Mezzaroma, S Carbone, ... International Journal of Cardiology 209, 215-220, 2016 | 199 | 2016 |
| NLRP3 inflammasome inhibitor ameliorates amyloid pathology in a mouse model of Alzheimer’s disease J Yin, F Zhao, JE Chojnacki, J Fulp, WL Klein, S Zhang, X Zhu Molecular neurobiology 55, 1977-1987, 2018 | 198 | 2018 |
| Pharmacologic inhibition of the NLRP3 inflammasome preserves cardiac function after ischemic and nonischemic injury in the mouse C Marchetti, S Toldo, J Chojnacki, E Mezzaroma, K Liu, FN Salloum, ... Journal of cardiovascular pharmacology 66 (1), 1-8, 2015 | 158 | 2015 |
| Design and biological characterization of hybrid compounds of curcumin and thalidomide for multiple myeloma K Liu, D Zhang, J Chojnacki, Y Du, H Fu, S Grant, S Zhang Organic & biomolecular chemistry 11 (29), 4757-4763, 2013 | 96 | 2013 |
| Discovery of 5-(4-hydroxyphenyl)-3-oxo-pentanoic acid [2-(5-methoxy-1H-indol-3-yl)-ethyl]-amide as a neuroprotectant for Alzheimer’s disease by hybridization of curcumin and … JE Chojnacki, K Liu, X Yan, S Toldo, T Selden, M Estrada, ... ACS chemical neuroscience 5 (8), 690-699, 2014 | 88 | 2014 |
| Development and Characterization of a Hydroxyl-Sulfonamide Analogue, 5-Chloro-N-[2-(4-hydroxysulfamoyl-phenyl)-ethyl]-2-methoxy-benzamide, as a Novel … C Guo, JW Fulp, Y Jiang, X Li, JE Chojnacki, J Wu, XY Wang, S Zhang ACS chemical neuroscience 8 (10), 2194-2201, 2017 | 83 | 2017 |
| Bivalent ligand containing curcumin and cholesterol as a fluorescence probe for Aβ plaques in Alzheimer’s disease K Liu, TL Guo, J Chojnacki, HG Lee, X Wang, SL Siedlak, W Rao, X Zhu, ... ACS chemical neuroscience 3 (2), 141-146, 2012 | 80 | 2012 |
| Curcumin/Melatonin Hybrid 5-(4-Hydroxy-phenyl)-3-oxo-pentanoic Acid [2-(5-Methoxy-1H-indol-3-yl)-ethyl]-amide Ameliorates AD-Like Pathology in the APP/PS1 … G Gerenu, K Liu, JE Chojnacki, JM Saathoff, P Martínez-Martín, G Perry, ... ACS chemical neuroscience 6 (8), 1393-1399, 2015 | 65 | 2015 |
| BF3· OEt2-promoted concise synthesis of difluoroboron-derivatized curcumins from aldehydes and 2, 4-pentanedione K Liu, J Chen, J Chojnacki, S Zhang Tetrahedron letters 54 (16), 2070-2073, 2013 | 60 | 2013 |
| Dissecting the sequence determinants for dephosphorylation by the catalytic subunits of phosphatases PP1 and PP2A B Hoermann, T Kokot, D Helm, S Heinzlmeir, JE Chojnacki, T Schubert, ... Nature Communications 11 (1), 3583, 2020 | 36 | 2020 |
| Bivalent ligands incorporating curcumin and diosgenin as multifunctional compounds against Alzheimer’s disease JE Chojnacki, K Liu, JM Saathoff, S Zhang Bioorganic & Medicinal Chemistry 23 (22), 7324-7331, 2015 | 35 | 2015 |
| Bivalent compound 17MN exerts neuroprotection through interaction at multiple sites in a cellular model of Alzheimer’s disease K Liu, JE Chojnacki, EE Wade, JM Saathoff, EJ Lesnefsky, Q Chen, ... Journal of Alzheimer's Disease 47 (4), 1021-1033, 2015 | 13 | 2015 |
| Mechanistic insight of bivalent compound 21MO as potential neuroprotectant for Alzheimer’s disease JM Saathoff, K Liu, JE Chojnacki, L He, Q Chen, EJ Lesnefsky, S Zhang Molecules 21 (4), 412, 2016 | 11 | 2016 |
| Structural and mechanistic insights into the interaction of the circadian transcription factor BMAL1 with the KIX domain of the CREB-binding protein A Garg, R Orru, W Ye, U Distler, JE Chojnacki, M Köhn, S Tenzer, ... Journal of Biological Chemistry 294 (45), 16604-16619, 2019 | 10 | 2019 |
| PLDMS: Phosphopeptide Library Dephosphorylation Followed by Mass Spectrometry Analysis to Determine the Specificity of Phosphatases for Dephosphorylation Site Sequences T Kokot, B Hoermann, D Helm, JE Chojnacki, MM Savitski, M Köhn Computational Methods for Predicting Post-Translational Modification Sites …, 2022 | 3 | 2022 |
| Membrane targeting with palmitoylated lysine added to PP1‐disrupting peptide induces PP1‐independent signaling JE Chojnacki, L Scheinost, Y Wang, M Köhn Journal of Peptide Science 29 (6), e3469, 2023 | | 2023 |
| O2‐13‐06: Development of NLRP3 Inflammasome Inhibitors for Alzheimer's Disease S Zhang, JE Chojnacki, J Fulp, D Sun Alzheimer's & Dementia 12, P262-P262, 2016 | | 2016 |
| P1‐305: Design and evaluation of fluorescent probes to elucidate the mechanism of curcumin/melatonin hybrids for Alzheimer's disease JM Saathoff, JE Chojnacki, K Liu, S Zhang Alzheimer's & Dementia 11 (7S_Part_10), P473-P473, 2015 | | 2015 |
| P4‐170: Mechanistic studies of a bivalent compound containing curcumin and a membrane anchorage as a neuroprotectant in mc65 cell model K Liu, JE Chojnacki, JM Saathoff, E Wade, X Yan, S Zhang Alzheimer's & Dementia 11 (7S_Part_18), P844-P844, 2015 | | 2015 |
